Kangkan Deka
Overview
Explore the profile of Kangkan Deka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kakoti B, Zothantluanga J, Deka K, Halder R, Roy D
In Silico Pharmacol
. 2025 Jan;
13(1):12.
PMID: 39780772
Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-024-00295-0.
2.
Devi C, Deka K, Das A, Talukdar A, Sola P
Mol Biotechnol
. 2024 Sep;
PMID: 39327380
Glioma is the most common and aggressive type of central nervous system tumor as categorized by the World Health Organization. Glioblastoma (GBA), in general, exhibits a grim prognosis and short...
3.
Kakoti B, Alom S, Deka K, Halder R
J Diabetes Metab Disord
. 2024 Jun;
23(1):441-459.
PMID: 38932895
Purpose: In this extensive review work, the important role of AMP-activated protein kinase (AMPK) in causing of diabetes mellitus has been highlighted. Structural feature of AMPK as well its regulations...
4.
Bezbaruah R, Chavda V, Nongrang L, Alom S, Deka K, Kalita T, et al.
Vaccines (Basel)
. 2022 Nov;
10(11).
PMID: 36423041
Vaccination is still the most cost-effective way to combat infectious illnesses. Conventional vaccinations may have low immunogenicity and, in most situations, only provide partial protection. A new class of nanoparticle-based...
5.
Chavda V, Bezbaruah R, Deka K, Nongrang L, Kalita T
Vaccines (Basel)
. 2022 Nov;
10(11).
PMID: 36423021
The world has not yet completely overcome the fear of the havoc brought by SARS-CoV-2. The virus has undergone several mutations since its initial appearance in China in December 2019....